Antiviral Agents against Emerging Viruses, Gebunden
Antiviral Agents against Emerging Viruses
Sie können den Titel schon jetzt bestellen. Versand an Sie erfolgt gleich nach Verfügbarkeit.
- Herausgeber:
- Erik De Clercq, Roberto Di Santo
- Verlag:
- Springer Nature Switzerland AG, 10/2026
- Einband:
- Gebunden
- Sprache:
- Englisch
- ISBN-13:
- 9783032306197
- Artikelnummer:
- 12909057
- Umfang:
- 264 Seiten
- Erscheinungstermin:
- 30.10.2026
- Serie:
- Topics in Medicinal Chemistry
- Hinweis
-
Achtung: Artikel ist nicht in deutscher Sprache!
Klappentext
This book reviews the current landscape of antiviral drug discovery with a strong focus on viral enzymes as therapeutic targets. It presents a timely, mechanismdriven overview of approved drugs, clinical candidates, and emerging inhibitor classes developed against major human pathogens, including HIV1, SARSCoV2, West Nile virus, CrimeanCongo hemorrhagic fever virus, and other hemorrhagic fever viruses. By integrating historical perspectives with recent breakthroughs, the volume highlights both the progress achieved and the challenges that remain in antiviral therapeutics.
The chapters cover key viral targets such as integrase, polymerase, helicase, RNase H, and viral proteases, discussing their structure, function, and role in viral replication. Several contributions focus on SARSCoV2, addressing polymerase, helicase, and protease inhibitors, while others examine antiviral strategies for flaviviruses and emerging hemorrhagic fever viruses that still lack effective treatments. Together, the chapters provide a coherent overview of targetbased antiviral research across diverse virus families.
This book appeals to researchers, advanced students, and professionals in medicinal chemistry, virology, pharmacology, and drug discovery, as well as to clinicians and translational scientists seeking an uptödate reference on antiviral targets and inhibitor development for both established and emerging viral infections.
Biografie (Erik De Clercq)
Erik De Clercq, M.D., PhD is currently President of the Rega Foundation, a member of the Belgian (Flemish) Royal Academy of Medicine and of the Academia Europaea, and a Fellow of the American Association for the Advancement of Science. He is an active Emeritus Professor of the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. He is honorary doctor of the Universities of Ghent, Belgium, Athens, Greece, Ferrara, Italy, Jinan (Shandong), China, Charles (Prague), Czech Republic, and Jihoceska (Bude?jovice), Czech Republic.§For his pioneering efforts in antiviral research, Professor De Clercq received in 1996 the Aventis award from the American Society for Microbiology, and in 2000 the Maisin Prize for Biomedical Sciences from the Belgian National Science Foundation. In 2008 he was elected Inventor of the Year by the European Union. Together with Dr. Anthony Fauci, Prof. De Clercq received the Dr. Paul Janssen Award for Biomedical Research in 2010.§He is the (co)inventor of a number of antiviral drugs, used for the treatment of HSV (valaciclovir, Valtrex , Zelitrex ), VZV (brivudin, Zostex , Brivirac , Zerpex ), CMV (cidofovir, Vistide ), HBV (adefovir dipivoxil, Hepsera ), and HIV infections (AIDS) (tenofovir disoproxil fumarate, Viread ).